AbbVie Partners with Chicago Cubs on "Striking Out Cancer"

AbbVie Partners with Chicago Cubs on "Striking Out Cancer"

Chicago -based institutions aim to create greater awareness for cancer advocacy and to support non-profit cancer organizations

AbbVie (NYSE: ABBV) announced a multi-year partnership with the Chicago Cubs to support people living with cancer through a campaign called "Striking Out Cancer" which starts today when the Chicago Cubs play the Cincinnati Reds. As part of the first year of the partnership, AbbVie will make a $233 donation for every strikeout by a Chicago Cubs pitcher at home during the 2025 regular season. The donation amount is in honor of the approximately 233 Americans diagnosed with cancer every hour, according to the American Cancer Society. 1

"Every strikeout this Chicago Cubs season is more than a statistic on the scoreboard – it is a step forward in supporting those living with and fighting cancer," said Tracie Haas , senior vice president, corporate affairs, AbbVie. "Together with our hometown partner the Chicago Cubs, we aim to create greater awareness for cancer advocacy and to make a remarkable impact for those living with cancer worldwide."

The total amount raised throughout the 2025 regular season will be donated to Cubs Charities in support of not-for-profit organizations working to advance the fight against cancer. This year's donations will be provided to Conquer Cancer®, the ASCO Foundation, a 501(c)(3) charitable organization focused on accelerating breakthroughs in lifesaving research and empowering people everywhere to conquer cancer, among other cancer not-for-profit organizations.

The campaign aligns with AbbVie's mission as a global biopharmaceutical company that discovers and delivers transformative medicines that help to solve serious health issues across several therapeutic areas including immunology, oncology, neuroscience and eye care, and products and services in our Allergan Aesthetics portfolio. In oncology, AbbVie's therapies for leukemias, lymphomas, lung and gynecological cancers are helping  patients across the world.

"We're honored to team up with AbbVie and do our part to help strikeout cancer," said Alex Seyferth , vice president, Cubs Corporate Partnerships. "Every dollar raised will go to organizations on the front line of fighting this terrible disease. Together, the Cubs and AbbVie are committed to raising awareness and donations to help those impacted by cancer."

"We're incredibly grateful to be a beneficiary of the 'Striking Out Cancer' campaign," said Nancy R. Daly , chief executive officer, Conquer Cancer. "The support from AbbVie and Cubs Charities is vital, enabling us to advance our critical work and bringing us closer to achieving our vision of a world where cancer is prevented or cured, and every survivor is healthy."

The "Striking Out Cancer" campaign launches in May 2025 and will run through the end of the 2025 Chicago Cubs regular season in its first year.

About AbbVie  
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com . Follow @abbvie on LinkedIn,   Facebook , Instagram , X (formerly Twitter) , and YouTube.

About the Chicago Cubs
The Chicago Cubs franchise, a charter member of Major League Baseball's National League since 1876, has won the National League pennant 17 times and was the first team to win back-to-back World Series titles in the 1907 and 1908 seasons. In 2016, the Chicago Cubs made history again when the team won its first World Series in 108 years, ending the longest championship drought in North American sports. Known for its ivy-covered outfield walls, hand-operated scoreboard and famous Marquee, iconic Wrigley Field has been the home of the Chicago Cubs since 1916 and is the second oldest ballpark in Major League Baseball. In 2009, the Ricketts family assumed ownership of the Chicago Cubs. The organization's three main goals are: Win the World Series, Create the World's Best Guest Experience and Be a Good Neighbor. For more information, visit www.cubs.com .

About Cubs Charities
Cubs Charities is a nonprofit that mobilizes the power of sport to champion youth, families and communities. Cubs Charities' work is focused on sports-based youth development and academic programming, investments in safe places to play and strategic grantmaking. Since 2009, Cubs Charities has invested more than $51 million in people, places and programs across Chicago . Cubs Charities is a leader among professional sports teams in its creation, execution and delivery of quality, sports-based youth development programming. Today, Cubs Charities' portfolio includes programs that provide children and youth with skilled coaches, quality programming and safe and accessible places to play the game. Learn more at www.cubscharities.org . and follow @CubsCharities on social media.

About Conquer Cancer®, the ASCO Foundation
Conquer Cancer funds research for every cancer, to help every patient, everywhere. Since 1984, its Grants & Awards program has awarded more than $203 million through more than 9,800 grants and awards to improve cancer care and accelerate breakthroughs in clinical and translational oncology research. Conquer Cancer donors support vital programs needed to deliver the highest quality patient care and share a vision of a world where cancer is prevented or cured, and every survivor is healthy. For more information visit CONQUER.ORG .

U.S. Media:

Investors:



Gabrielle Tarbert

Liz Shea

gabrielle.tarbert@abbvie.com

liz.shea@abbvie.com



Ilke Limoncu


ilke.limoncu@abbvie.com


1 https://cancerstatisticscenter.cancer.org/

AbbVie logo

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/abbvie-partners-with-chicago-cubs-on-striking-out-cancer-302469190.html

SOURCE AbbVie

News Provided by PR Newswire via QuoteMedia

ABBV:US
The Conversation (0)
AbbVie Inc.

AbbVie Inc.

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This establishes the timeline for the planned safety and efficacy futility interim analysis by an independent Data Monitoring Committee (DMC).

Keep reading...Show less
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less
Zoono Group

Exclusive UK Packaging Agreement signed between Sharpak Aylesham Limited, Zoono, and OSY

Zoono Group Limited (Company) (ASX: ZNO) is pleased to update the market on an exclusive contract signed with Sharpak Aylesham Limited (Sharpak) and the Company’s partner in the food supply chain sector, OSY Group Limited (OSY).

Keep reading...Show less
Amplia Therapeutics

Accent Trial Data Demonstrates that Narmafotinib + Chemotherapy Combination Superior to Chemotherapy Alone

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce important new data from our ongoing ACCENT clinical trial in pancreatic cancer. The trial is investigating the Company’s best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane. Fifteen (15) confirmed partial responses (PRs) have now been recorded in the trial, a level of response sufficient to demonstrate that the combination of narmafotinib and chemotherapy is superior to chemotherapy alone.
Keep reading...Show less

Latest Press Releases

Related News

×